KRAS and non-small cell lung carcinoma: Although CDKN2A alterations generally appear to be a poor prognostic factor, associated with worse outcomes not only with KRAS G12C inhibitors but also ICI and EGFR inhibitors61,62, the observed similar prevalence of CDKN2A co-alterations in both KRAS and EGFR-mutant non-Sq NSCLC across ancestry groups is unlikely to impact treatment outcomes across ancestry groups.